What the quality statement means for service providers, healthcare professionals and commissioners. This standard should be read in conjunction with QS3, QS6, QS9, QS11, QS21, QS28, QS84, QS15, QS2 and QS100.
Introduction Introduction
This quality standard covers the treatment and management of atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (18 years and older). For more information see the topic overview. Both valvular and non-valvular atrial fibrillation are covered unless specified otherwise in the statement.
Why this quality standard is needed
Atrial fibrillation is a condition that affects the heart, causing it to beat irregularly and too fast.
When this happens, blood does not flow properly through the heart and the rest of the body. This means that people with atrial fibrillation may be at increased risk of blood clots. Clots can block blood vessels, and a stroke can occur if a blood vessel in the brain is blocked by a clot. As a result, if left untreated atrial fibrillation is a significant risk factor for stroke and other morbidities.
Atrial fibrillation is the most common sustained cardiac arrhythmia, and estimates suggest that its prevalence is increasing. The Health and Social Care Information Centre's 2011-12 Quality and outcomes framework estimated the prevalence of known atrial fibrillation to be 1.57%. The NHS Improving Quality Guidance on risk assessment and stroke prevention for atrial fibrillation (GRASP-AF) tool estimated the prevalence to be between 1.65% and 1.76%. However, it has been shown that the true prevalence of atrial fibrillation is underestimated and could be around 2.0% The management of atrial fibrillation aims to prevent complications, particularly stroke, and alleviate symptoms. Drug treatments include anticoagulants to reduce the risk of stroke, antiarrhythmics to restore or maintain normal heart rhythm and drugs to slow the heart rate in adults who remain in atrial fibrillation. Non-pharmacological management includes electrical cardioversion, which may be used to 'shock' the heart back to its normal rhythm, and catheter or surgical ablation to create lesions to stop the abnormal electrical impulses that cause atrial
The quality standard is expected to contribute to improvements in the following outcomes: mortality rates in adults with atrial fibrillation stroke and transient ischaemic attack rates in adults with atrial fibrillation admission rates for adults with a primary diagnosis of atrial fibrillation quality of life of adults with atrial fibrillation.
How this quality standard supports delivery of outcome frameworks
NICE quality standards are a concise set of prioritised statements designed to drive measurable improvements in the 3 dimensions of quality -patient safety, patient experience and clinical effectiveness -for a particular area of health or care. They are derived from high-quality guidance, such as that from NICE or other sources accredited by NICE. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the Tables 1 and 2 show the outcomes, overarching indicators and improvement areas from the frameworks that the quality standard could contribute to achieving.
T 
Patient experience and safety issues
Ensuring that care is safe and that people have a positive experience of care is vital in a high-quality service. It is important to consider these factors when planning and delivering services relevant to atrial fibrillation.
NICE has developed guidance and an associated quality standard on patient experience in adult NHS services (see the NICE Pathway on patient experience in adult NHS services), which should be considered alongside this quality standard. They specify that people receiving care should be treated with dignity, have opportunities to discuss their preferences, and are supported to understand their options and make fully informed decisions. They also cover the provision of information to patients and service users. Quality statements on these aspects of patient experience are not usually included in topic-specific quality standards. However, recommendations in the development sources for quality standards that impact on patient experience and are specific to the topic are considered during quality statement development.
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Coordinated services
The quality standard for atrial fibrillation: treatment and management specifies that services should be commissioned from and coordinated across all relevant agencies encompassing the whole atrial fibrillation care pathway. A person-centred, integrated approach to providing services is fundamental to delivering high-quality care to adults with atrial fibrillation.
The Health and Social Care Act 2012 sets out a clear expectation that the care system should consider NICE quality standards in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Commissioners and providers of health and social care
should refer to the library of NICE quality standards when designing high-quality services. Other quality standards that should also be considered when choosing, commissioning or providing a high-quality atrial fibrillation service are listed in related quality standards.
T Tr raining and competencies aining and competencies
The quality standard should be read in the context of national and local guidelines on training and competencies. All healthcare professionals involved in assessing, caring for and treating adults with atrial fibrillation should have sufficient and appropriate training and competencies to deliver the actions and interventions described in the quality standard. Quality statements on staff training and competency are not usually included in quality standards. However, recommendations in the development sources on specific types of training for the topic that exceed standard professional training are considered during quality statement development.
Role of families and carers Role of families and carers
Quality standards recognise the important role families and carers have in supporting adults with atrial fibrillation. If appropriate, healthcare professionals should ensure that family members and carers are involved in the decision-making process about investigations, treatment and care.
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List of quality statements List of quality statements 
Quality statement 1: Anticoagulation to reduce strok Quality statement 1: Anticoagulation to reduce stroke risk e risk
Quality statement
Adults with non-valvular atrial fibrillation and a CHA 2 DS 2 -VAS C stroke risk score of 2 or above are offered anticoagulation.
Rationale
Adults with non-valvular atrial fibrillation and a CHA 2 DS 2 -VAS C stroke risk score of 2 or above are at a much higher risk of having a stroke than the general population. Anticoagulation therapy can help to prevent strokes by reducing the likelihood of a blood clot forming. A person's bleeding risk should be taken into account in reaching a decision about anticoagulation, although for most people the benefit of anticoagulation outweighs the bleeding risk.
Quality measures
Structure Structure
Evidence of local arrangements and written clinical protocols to ensure that adults with non-valvular atrial fibrillation and a CHA 2 DS 2 -VAS C stroke risk score of 2 or above are offered anticoagulation.
Data sour
Data source: ce: Local data collection.
Process Process
Proportion of adults with non-valvular atrial fibrillation and a CHA 2 DS 2 -VAS C stroke risk score of 2 or above who receive anticoagulation.
Numerator -the number in the denominator who receive anticoagulation.
Denominator -the number of adults with non-valvular atrial fibrillation and a CHA 2 DS 2 -VAS C stroke risk score of 2 or above. (1 point).
The NICE guideline on atrial fibrillation recommends that bleeding risk, estimated using the HAS- 
Quality statement
Adults with atrial fibrillation are not prescribed aspirin as monotherapy for stroke prevention.
Rationale
The risks of taking aspirin outweigh any benefits of taking it as monotherapy for stroke prevention in adults with atrial fibrillation. Healthcare professionals should be aware that adults with atrial fibrillation may need to take aspirin for other indications.
Quality measures
Evidence of local monitoring arrangements to ensure that adults with atrial fibrillation are not prescribed aspirin as monotherapy for stroke prevention.
Data sour
Process Process
Proportion of adults with atrial fibrillation who are prescribed aspirin as monotherapy for stroke prevention.
Numerator -the number in the denominator who are prescribed aspirin as monotherapy for stroke prevention.
Denominator -the number of adults with atrial fibrillation.
Data sour Data source: ce: Local data collection. Data can be collected using the Royal College of Physicians'
Sentinel Stroke National Audit Programme (SSNAP), question 2.1.6.
Outcome Outcome
Rates of prescribing aspirin.
Data sour Data source: ce:Local data collection.
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What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders (primary and secondary care services) monitor prescribing of pharmacological treatment(s) for adults with atrial fibrillation and have protocols in place to ensure that aspirin is not prescribed as monotherapy for stroke prevention.
Healthcare professionals Healthcare professionals do not prescribe aspirin as monotherapy for stroke prevention for adults with atrial fibrillation.
Commissioners Commissioners (NHS England area teams and clinical commissioning groups) specify that primary and secondary care services ensure that aspirin is not prescribed as monotherapy for stroke prevention for adults with atrial fibrillation.
What the quality statement means for patients, service users and carers
Adults with atrial fibrillation Adults with atrial fibrillation are not prescribed aspirin on its own for preventing stroke.
Source guidance
Atrial fibrillation (2014) NICE guideline CG180, recommendation 1.5.15 (key priority for implementation) 
Definitions of terms used in this quality statement
Quality measures
Structure Structure
Evidence of local arrangements to ensure that adults with atrial fibrillation who are prescribed anticoagulation can discuss the options with their healthcare professional at least once a year.
Process Process
Proportion of adults with atrial fibrillation who are prescribed anticoagulation who discuss the options with their healthcare professional at least once a year.
Numerator -the number in the denominator who discuss the options with their healthcare professional at least once a year.
Denominator -the number of adults with atrial fibrillation who are prescribed anticoagulation. 
Data sour
What the quality statement means for patients, service users and carers
Adults with atrial fibrillation who are prescribed an anticoagulant Adults with atrial fibrillation who are prescribed an anticoagulant have the chance to talk with their doctor at least once a year about the types of anticoagulant they could have and the advantages and disadvantages of each.
Source guidance
Atrial fibrillation (2014) NICE guideline CG180, recommendations 1.5.4, 1.5.6, 1.5.8 and 1.5.10
Definitions of terms used in this quality statement
Anticoagulants Anticoagulants
Anticoagulants for people with atrial fibrillation include vitamin K antagonists (such as warfarin)
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and non-vitamin K antagonist oral anticoagulants (NOACS; that is, apixaban, dabigatran etexilate, edoxaban and rivaroxaban).
[Adapted from Atrial fibrillation (NICE guideline CG180) and Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE technology appraisal guidance 355)]
Discuss Discuss
Any discussion with an adult with atrial fibrillation should involve both oral and written information. A patient decision aid, such as that accompanying NICE's guideline on atrial fibrillation, can be used to inform the discussion. A discussion should take place at least once a year to review the need and quality of anticoagulation.
[ 
Source guidance
Atrial fibrillation (2014) NICE guideline CG180, recommendations 1.5.11 (key priority for implementation), 1.5.12, 1.5.13 and 1.5.14 (key priority for implementation) 2 INR values higher than 5 or 1 INR value higher than 8 within the past 6 months 2 INR values less than 1.5 within the past 6 months TTR less than 65%.
The NICE guideline on atrial fibrillation recommends that TTR is measured at each visit and at least annually, and that healthcare professionals should:
use a validated method of measurement such as the Rosendaal method for computer-assisted dosing or proportion of tests in range for manual dosing exclude measurements taken during the first 6 weeks of treatment calculate TTR over a maintenance period of at least 6 months.
[Atrial fibrillation (NICE guideline CG180), recommendations 1.5.11, 1.5.12 and 1.5.18]
Reassessing anticoagulation Reassessing anticoagulation
The NICE guideline on atrial fibrillation recommends that the following factors should be taken into account and addressed if they are contributing to poor anticoagulation control:
cognitive function adherence to prescribed therapy illness interacting drug therapy lifestyle factors including diet and alcohol consumption.
If poor anticoagulation control cannot be improved as a result of this reassessment, the risks and benefits of alternative stroke prevention strategies should be evaluated and discussed with the person.
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Quality statement 5: Referr Quality statement 5: Referral for specialised management al for specialised management
Quality statement
Adults with atrial fibrillation whose treatment fails to control their symptoms are referred for specialised management within 4 weeks.
Rationale
Prompt referral of adults with atrial fibrillation to specialised management if treatment fails can help to alleviate symptoms and reduce the likelihood of poor outcomes such as stroke and heart failure.
Quality measures
Evidence of local arrangements and referral pathways to ensure that adults with atrial fibrillation whose treatment fails to control their symptoms are referred for specialised management within 4 weeks.
Data sour
Process Process
Proportion of adults with atrial fibrillation whose treatment fails to control their symptoms who are referred for specialised management within 4 weeks.
Numerator -the number in the denominator who are referred for specialised management within 4 weeks.
Denominator -the number of adults with atrial fibrillation whose treatment fails to control their symptoms.
Data sour
Outcome Outcome a) Adults with atrial fibrillation symptom control. 
What the quality statement means for patients, service users and carers
Adults with atrial fibrillation who still ha Adults with atrial fibrillation who still hav ve symptoms after treatment e symptoms after treatment are referred within 4 weeks for specialised care that aims to ease their symptoms and reduce their risk of having a stroke or heart failure.
Source guidance
Atrial fibrillation (2014) NICE guideline CG180, recommendation 1.3.1 (key priority for implementation)
Definitions of terms used in this quality statement
Fails to control symptoms Fails to control symptoms Adults whose treatment fails to control the symptoms of atrial fibrillation at any stage.
[Adapted from Atrial fibrillation (NICE guideline CG180), recommendation 1.3.1]
Quality statement Quality statement 6 ( 6 (de dev velopmental): Self-monitoring of anticoagulation elopmental): Self-monitoring of anticoagulation Developmental quality statements set out an emergent area of cutting-edge service delivery or technology currently found in a minority of providers and indicating outstanding performance.
They will need specific, significant changes to be put in place, such as redesign of services or new equipment.
Developmental quality statement
Adults with atrial fibrillation on long-term vitamin K antagonist therapy are supported to self-manage with a coagulometer.
Rationale
Enabling adults with atrial fibrillation to self-manage their coagulation using a coagulometer can help to optimise their anticoagulation treatment. As well as reducing the frequency of hospital or clinic visits, it can improve health outcomes such as risk of stroke and bleeding.
Quality measures
Evidence of local arrangements for adults with atrial fibrillation on long-term vitamin K antagonist therapy to be supported to self-manage with a coagulometer.
Data sour
Process Process
Proportion of adults with atrial fibrillation on long-term vitamin K antagonist therapy who are supported to self-manage with a coagulometer.
Numerator -the number in the denominator who are supported to self-manage with a coagulometer.
Denominator -the number of adults with atrial fibrillation on long-term vitamin K antagonist therapy.
Data sour
Data source: ce: Local data collection. Support Support
Patients and carers should be trained in the effective use of the CoaguChek XS system and clinicians involved in their care should regularly review their ability to self-monitor. Equipment for self-monitoring should be regularly checked using reliable quality-control procedures, and by testing patients' equipment against a healthcare professional's coagulometer which is checked in line with an external quality assurance scheme. Ensure accurate patient records are kept and shared appropriately.
[Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (2014, updated 2017) NICE diagnostics guidance 14, recommendations 1.3 and 1.4]
Equality and diversity considerations
For adults with atrial fibrillation who may have difficulty with or who are unable to self-monitor, such as people with disabilities, the possibility of their carers helping with self-monitoring should be considered. Coagulometers currently come at a cost to the adult with atrial fibrillation, so reasonable adjustments should be made for the socioeconomic status of the adult.
Atrial fibrillation (QS93)
Using the quality standard Using the quality standard
Quality measures
The quality measures accompanying the quality statements aim to improve the structure, process and outcomes of care in areas identified as needing quality improvement. They are not a new set of targets or mandatory indicators for performance management.
See NICE's how to use quality standards for further information, including advice on using quality measures.
Levels of achievement
Expected levels of achievement for quality measures are not specified. Quality standards are intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 0% if the quality statement states that something should not be done). However, NICE recognises that this may not always be appropriate in practice, taking account of safety, choice and professional judgement, and therefore desired levels of achievement should be defined locally.
Using other national guidance and policy documents
Other national guidance and current policy documents have been referenced during the development of this quality standard. It is important that the quality standard is considered alongside the documents listed in development sources.
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Div Diversity ersity, equality and language , equality and language During the development of this quality standard, equality issues have been considered and equality assessments are available.
Good communication between healthcare professionals and adults with atrial fibrillation is essential. Treatment, care and support, and the information given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English. Adults with atrial fibrillation should have access to an interpreter or advocate if needed.
Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties. 
Future quality standards
This quality standard has been developed in the context of all quality standards referred to NICE, including the following topics scheduled for future development:
Physical activity: encouraging activity within the general population
Primary prevention: population and community based primary prevention strategies, including the role of A&E, at different stages of the life course.
The full list of quality standard topics referred to NICE is available from the quality standards topic library on the NICE website. 
